Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Anakinra injection Clear all
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Biologic Therapy to Prevent Osteoarthritis After ACL Injury

NCT03968913
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries
Interventions
Anakinra injection, sterile saline injection
Drug · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 6, 2026, 2:06 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

NCT03265132
View directory record Official record
Conditions
Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset
Interventions
anakinra, Placebo
Biological · Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Beverly Hills, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 6, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Anakinra to Prevent Adverse Post-infarction Remodeling (2)

NCT01175018
View directory record Official record
Conditions
Acute Myocardial Infarction, Heart Failure
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 110 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 22, 2016 · Synced Sep 6, 2026, 2:06 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis

NCT01809132
View directory record Official record
Conditions
Acute Alcoholic Hepatitis
Interventions
Anakinra, Pentoxifylline, Zinc Sulfate, Methylprednisolone
Drug
Lead sponsor
Mack Mitchell
Other
Eligibility
21 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
4
States / cities
Louisville, Kentucky • Worcester, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 6, 2026, 2:06 PM EDT
Terminated Phase 2 Interventional Results available

Treatment of Acute Pericarditis With Anakinra

NCT03224585
View directory record Official record
Conditions
Acute Pericarditis
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Sep 6, 2026, 2:06 PM EDT
Terminated Phase 2 Interventional Results available

IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions

NCT02930122
View directory record Official record
Conditions
Anterior Cruciate Ligament Tear
Interventions
anakinra (150mg), Saline intraarticularly
Drug · Other
Lead sponsor
Cale Jacobs, PhD
Other
Eligibility
14 Years to 40 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Sep 6, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Interleukin-1 Blockade for Treatment of Cardiac Sarcoidosis

NCT04017936
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
Anakinra
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 6, 2026, 2:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease

NCT01267994
View directory record Official record
Conditions
Sensorineural Hearing Loss, Autoimmune Inner Ear Disease
Interventions
Anakinra
Drug
Lead sponsor
Andrea Vambutas
Other
Eligibility
13 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Sep 6, 2026, 2:06 PM EDT
Recruiting Phase 2 Interventional

Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease

NCT03587701
View directory record Official record
Conditions
Autoimmune Inner Ear Disease, Meniere's Disease
Interventions
Anakinra 100Mg/0.67Ml Inj Syringe (Period 1), Placebo injection (Period 1), Anakinra 100Mg/0.67Ml Inj Syringe (Period 2), Placebo injection (Period 2)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 6, 2026, 2:06 PM EDT
Completed Not applicable Interventional Results available

Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction

NCT01542502
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Sep 6, 2026, 2:06 PM EDT
Terminated Phase 1 Interventional

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

NCT02780583
View directory record Official record
Conditions
Macrophage Activation Syndrome
Interventions
kineret, placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Year and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 6, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2

NCT02278562
View directory record Official record
Conditions
ESRD
Interventions
anakinra, actos, placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 6, 2026, 2:06 PM EDT
Not listed Early Phase 1 Interventional

Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms

NCT03991520
View directory record Official record
Conditions
Endometriosis, Anakinra, Markers of Inflammation
Interventions
Anakinra 100Mg/0.67Ml Inj Syringe, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 6, 2026, 2:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure

NCT01300650
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Sep 6, 2026, 2:06 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)

NCT01950299
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Anakinra 100 mg, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 99 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 6, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis

NCT03002974
View directory record Official record
Conditions
Acute Gouty Arthritis
Interventions
Anakinra 100 mg, Triamcinolone Acetonide 40 mg, Placebo to Anakinra 100 mg, Placebo to Triamcinolone Acetonide 40 mg
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Sep 6, 2026, 2:06 PM EDT
Completed Phase 1 Interventional

Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Knee OA

NCT02790723
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
sc-rAAV2.5IL-1Ra
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Sep 6, 2026, 2:06 PM EDT
Active, not recruiting Phase 2 Interventional

Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure

NCT05177822
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 6, 2026, 2:06 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 6, 2026, 2:06 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)

NCT01936844
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra (high dose), Anakinra (standard dose), Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Sep 6, 2026, 2:06 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Discovery and Analytical Validation of Inflammatory Bio-signatures of the Human Pain Experience

NCT05074485
View directory record Official record
Conditions
Pain
Interventions
anakinra, Placebo, Nociceptive pain challenge
Drug · Other
Lead sponsor
Alan Prossin
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Sep 6, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2

NCT03797001
View directory record Official record
Conditions
Heart Failure, Systolic, Inflammation
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 6, 2026, 2:06 PM EDT
Completed Phase 2 Interventional Results available

Anakinra for Inflammatory Pustular Skin Diseases

NCT01794117
View directory record Official record
Conditions
Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 110 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 6, 2026, 2:06 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss

NCT02414152
View directory record Official record
Conditions
Hearing Loss, Sudden
Interventions
anakinra
Drug
Lead sponsor
Andrea Vambutas
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 6, 2026, 2:06 PM EDT